ACRS Aclaris Therapeutics Inc.

+0.08  (+2%)
Previous Close 5.11
Open 5.13
Price To Book 1.17
Market Cap 214,203,279
Shares 41,272,308
Volume 8,726
Short Ratio
Av. Daily Volume 522,219

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 2Q 2019.
ATI-502 (ATI-50002-AA-201) - dose ranging
Alopecia areata
Phase 2 open label 6-month data due mid-2019.
ATI-502 (VITI-201 Topical)
Phase 2 data due 2H 2019.
ATI-501 (AUAT-201 Oral)
Alopecia areata
Approval announced December 15, 2017.
ESKATA (hydrogen peroxide)
Seborrheic keratosis (SK)
Phase 3 data due 2H 2019.
A-101 THWART-1 and THWART-2
Common warts (verruca vulgaris)
Phase 2 interim data released June 28, 2018.
ATI-502 AA-202 Topical - PK/safety
Alopecia areata
Phase 2 6-month data noted increase in hair count of 8.6 hairs/cm2. 12 month data due YE 2019.
ATI-502 (ATI-50002-AGA-201) - open label
Androgenetic alopecia (AGA) - Hair loss
Phase 2 data due mid-2019.
ATI-502 (AD-201 Topical)
Atopic dermatitis (AD)
Phase 1/2 trial to be initiated 2H 2019.
Rheumatoid arthritis (RA)

Latest News

  1. Help may be on the way, via this Malvern biopharm firm, for male/female pattern baldness
  2. Aclaris Announces Positive Results From Alopecia Treatment Trial
  3. Aclaris Therapeutics Announces Positive 6-Month Results from a Phase 2 Open-Label Clinical Trial of ATI-502 Topical in Patients with Androgenetic Alopecia (Male/Female Pattern-Baldness)
  4. Aclaris Therapeutics to Present at the 2019 JMP Securities Life Sciences Conference
  5. Edited Transcript of ACRS earnings conference call or presentation 8-May-19 9:00pm GMT
  6. Aclaris Therapeutics to Present at Jefferies 2019 Global Healthcare Conference
  7. Rigel Initiates Enrollment in Pivotal Blood Disorder Study
  8. Aclaris Therapeutics, Inc. (ACRS) Q1 2019 Earnings Call Transcript
  9. Aclaris Therapeutics (ACRS) Reports Q1 Loss, Lags Revenue Estimates
  10. Aclaris: 1Q Earnings Snapshot
  11. Aclaris Therapeutics Reports First Quarter 2019 Financial Results and Provides Update on Clinical and Commercial Developments
  12. How Do Analysts See Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Performing In The Years Ahead?
  13. Aclaris Therapeutics to Announce First Quarter 2019 Financial Results on May 8, 2019
  14. Aclaris Therapeutics Submits Investigational New Drug Application for ATI-450, an oral MK2 inhibitor, for the Treatment of Rheumatoid Arthritis
  15. Aclaris Therapeutics Announces Issuance of a Patent Covering the use of Ruxolitinib and its Deuterated Forms to Treat Alopecia Areata
  16. Consider These 3 Falling Knives
  17. Edited Transcript of ACRS earnings conference call or presentation 18-Mar-19 12:00pm GMT
  18. Aclaris Therapeutics to Attend Upcoming Investor Conference
  19. Aclaris Therapeutics, Inc. (ACRS) Q4 2018 Earnings Conference Call Transcript